{"gene":"GALC","run_date":"2026-04-28T18:06:52","timeline":{"discoveries":[{"year":2018,"finding":"GALC forms a heterotetrameric complex with the saposin SapA to degrade glycosphingolipids: crystal structure of the GALC-SapA complex reveals an open channel connecting the enzyme active site to the SapA hydrophobic cavity, explaining how the soluble hydrolase cleaves the polar glycosyl headgroups of galactosylceramide from their hydrophobic ceramide tails.","method":"Crystal structure determination (structural biology) with functional validation","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mechanistic interpretation of substrate channeling; single rigorous paper with structural and functional detail","pmids":["29323104"],"is_preprint":false},{"year":1995,"finding":"GALC catalyzes lysosomal hydrolysis of galactosylceramide (galactocerebroside) and galactosylsphingosine (psychosine) as primary substrates; the enzyme is a lysosomal hydrolase (EC 3.2.1.46) purified from human urine and brain, and the GALC gene encodes 17 exons spanning ~60 kb.","method":"Biochemical purification, cDNA cloning, gene structure determination","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 — direct enzymatic characterization and gene structure; replicated across multiple studies","pmids":["7601472"],"is_preprint":false},{"year":1996,"finding":"GALC expressed via retroviral vector in fibroblasts is secreted into the media and taken up by neighboring untransduced cells; uptake is partially mannose-6-phosphate receptor-mediated, and internalized GALC localizes to lysosomes where it metabolizes galactosylceramide.","method":"Retroviral transduction, secretion assay, mannose-6-phosphate receptor inhibition, radiolabeled substrate metabolism in lysosomes","journal":"Biochemical and Molecular Medicine","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution of enzyme activity in recipient cells, subcellular localization confirmed, receptor pathway identified with direct inhibition","pmids":["8812733"],"is_preprint":false},{"year":2016,"finding":"Infantile-onset GALC mutants show reduced trafficking to lysosomes and reduced processing compared to later-onset mutants; lysosomal GALC activity (not total cell lysate activity) correlates with disease severity, and cis-polymorphisms modulate lysosomal trafficking and processing of GALC.","method":"Subcellular fractionation to isolate lysosomal fraction, enzyme activity assay in lysosomes vs. whole-cell lysates, trafficking analysis of mutant GALC proteins","journal":"The Journal of Neuroscience","confidence":"High","confidence_rationale":"Tier 2 — direct lysosomal fractionation with functional consequence, multiple mutants tested with orthogonal activity and trafficking assays","pmids":["26865610"],"is_preprint":false},{"year":2020,"finding":"GALC is required for macrophage degradation of myelin-derived galactosylceramide; GALC-deficient macrophages accumulate galactosylceramide and transform into globoid cells, causing secondary neuroinflammation independent of psychosine-induced demyelination. Cross-correction of GALC does not occur efficiently in vivo, and Schwann cells autonomously produce psychosine.","method":"Novel GLD mouse model with cell-type-specific GALC deficiency, in vivo macrophage exposure to galactosylceramide, hematopoietic stem cell transplantation experiments","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — genetic in vivo model with defined cellular phenotype, multiple orthogonal experiments demonstrating two distinct disease mechanisms","pmids":["32375064"],"is_preprint":false},{"year":2006,"finding":"The twitcher mouse nonsense mutation (W339X) in GALC causes nonsense-mediated mRNA decay (NMD) of GALC transcripts, resulting in undetectable truncated protein; NMD inhibitors (anisomycin, emetine, puromycin) restore GALC transcript levels in twitcher-derived Schwann cells.","method":"Western blot, quantitative RT-PCR, NMD inhibitor treatment in twitcher Schwann cell line (TwS1)","journal":"Neurobiology of Disease","confidence":"High","confidence_rationale":"Tier 2 — multiple inhibitors tested with quantitative mRNA measurements, mechanistically defining the cause of absent GALC protein","pmids":["16759875"],"is_preprint":false},{"year":1997,"finding":"The 5' flanking region of the human GALC gene contains a GC-rich promoter with Sp1 binding sites but no TATA or CAAT boxes; a construct from nucleotides -176 to -24 has strongest promoter activity, with inhibitory sequences upstream of the promoter and within the first 234 nucleotides of intron 1, explaining low GALC protein levels across all cell types.","method":"Chloramphenicol acetyltransferase (CAT) reporter assay with deletion constructs","journal":"Biochemical and Molecular Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — reporter gene assay directly measuring promoter activity; single study","pmids":["9441867"],"is_preprint":false},{"year":1996,"finding":"Expression studies in COS-1 cells confirmed that the A473C transversion (Y158S) in canine GALC is the disease-causing mutation in West Highland White and Cairn terriers with globoid cell leukodystrophy, while the C1915T change (P639S) is not causative.","method":"COS-1 cell expression system with site-specific mutation, enzyme activity assay","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct expression and enzyme activity measurement distinguishing disease-causing from non-causative mutation","pmids":["8661004"],"is_preprint":false},{"year":2007,"finding":"The GALC p.Gly41Ser missense mutation abolishes galactocerebrosidase catalytic activity, as confirmed by expression studies, and causes late-onset Krabbe disease as a founder mutation in the Catania region of Sicily.","method":"Expression studies with enzyme activity assay","journal":"Human Mutation","confidence":"Medium","confidence_rationale":"Tier 2 — direct enzyme activity measurement in expression system; single study","pmids":["17579360"],"is_preprint":false},{"year":1997,"finding":"An intronic IVS6+5G>A mutation in GALC causes exon 6 skipping, demonstrated by GALC mini-gene transfection experiments; the resulting transcript from the nonsense mutation allele undergoes rapid degradation consistent with NMD.","method":"Mini-gene transfection, mRNA analysis","journal":"Genetic Testing","confidence":"Medium","confidence_rationale":"Tier 2 — mini-gene functional splicing assay; single study","pmids":["10464649"],"is_preprint":false},{"year":2015,"finding":"N-octyl-4-epi-β-valienamine (NOEV) acts as a pharmacological chaperone for mutant GALC: it inhibits GALC activity in cell lysates, stabilizes GALC under heat denaturation, binds to the active site (structural modeling), and enhances maturation of GALC precursor to its mature active form, increasing activity of late-onset mutant GALC in COS1 cells and patient fibroblasts.","method":"Enzyme activity assay, heat denaturation protection assay, in vitro chaperone treatment in COS1 cells and patient fibroblasts, structural modeling","journal":"Journal of Human Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal in vitro assays; single lab, chaperone active-site binding defined","pmids":["26108143"],"is_preprint":false},{"year":2013,"finding":"The GALC E130K missense mutation causes loss of enzymatic activity despite normal precursor protein levels; the GALCtwi-5J mouse model shows that loss of GALC activity leads to psychosine accumulation and severe PNS hypomyelination/dysmyelination with preserved CNS myelin, suggesting primary dysmyelination mechanism distinct from the twitcher model.","method":"Mouse model with missense mutation, enzyme activity assay, neuropathology, psychosine measurement","journal":"Human Molecular Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo loss-of-function mouse model with specific cellular and biochemical phenotype; single study","pmids":["23620143"],"is_preprint":false},{"year":2006,"finding":"Lentiviral vector-expressed GALC accumulates in lysosomes of transduced neural cells (neurons, oligodendrocytes, astrocytes) and is also secreted into the extracellular medium; conditioned GALC medium corrects enzyme deficiency in non-transduced twitcher glial cultures.","method":"Lentiviral transduction, subcellular localization by immunostaining, conditioned medium cross-correction assay","journal":"The Journal of Gene Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular localization to lysosome with cross-correction functional assay; single study","pmids":["16732552"],"is_preprint":false},{"year":2017,"finding":"Heterozygous GALC mutant mice show reduced myelin debris clearance and diminished remyelination after cuprizone-induced demyelination; microglial phagocytic response and Trem2 elevation are markedly reduced in GALC+/- animals, and these defects can be corrected in vitro by NKH-477 treatment.","method":"Cuprizone demyelination model in GALC+/- mice, histology, Trem2 analysis, in vitro pharmacological rescue","journal":"Human Molecular Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — defined loss-of-function model with specific microglial/remyelination phenotype; single lab with pharmacological rescue validation","pmids":["28575206"],"is_preprint":false},{"year":2025,"finding":"In a zebrafish GALC model, galcb knockout (not galca) dramatically reduces total GALC activity; galcb KO zebrafish accumulate lactosylceramide (LacCer) rather than psychosine in brain, and intraventricular LacCer injection induces neuroinflammatory markers and macrophage infiltration, implicating LacCer as a neuroinflammatory metabolite in GALC deficiency.","method":"CRISPR/Cas9 knockout in zebrafish, GALC activity assay, targeted lipidomics, intraventricular LacCer injection, immunohistochemistry, gene expression analysis","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 — ortholog model with multiple orthogonal methods; novel mechanistic finding about LacCer role, single study","pmids":["40305757"],"is_preprint":false},{"year":2024,"finding":"Systematic expression of 31 clinically-relevant GALC missense variants in a GALC-knockout human oligodendrocytic cell line shows that infantile-onset variants retain <2% of wild-type activity, later-onset variants retain up to 7%, residual GALC activity correlates with mature lysosomal GALC protein levels (Pearson r=0.93), and many low-activity variants have defective lysosomal trafficking (mis-trafficking) while retaining secretion capacity.","method":"CRISPR-Cas9 GALC knockout cell line, transient expression assays, enzyme activity assay, lysosomal GALC protein quantification, secretion assays, psychosine measurement","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 — systematic quantitative functional analysis in relevant human cell model with multiple orthogonal methods; preprint, not yet peer-reviewed","pmids":["39464077"],"is_preprint":true},{"year":2023,"finding":"GALC knockout by CRISPR-Cas9 in neuronal cell models does not lead to alpha-synuclein accumulation, suggesting that increased rather than reduced galactosylceramidase activity may be associated with Parkinson's disease; structural analysis indicates the common variant p.I562T leads to improper GALC maturation affecting activity.","method":"CRISPR-Cas9 knockout, alpha-synuclein immunoassay, in silico structural analysis, GBA activity assay","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 — direct KO experiment with specific phenotypic readout; single study","pmids":["36370000"],"is_preprint":false},{"year":2020,"finding":"iPSC-derived microglia from Krabbe patients form globoid cells when fed galactosylceramide (GalCer), with accumulation of autophagy proteins and LAMP1 reduction, demonstrating that GalCer loading triggers lysosomal dysfunction and globoid cell transformation; Krabbe myelinating organoids show early myelination defects without autophagy or mTOR pathway dysregulation.","method":"iPSC-derived microglia and myelinating organoids, GalCer feeding assay, LAMP1 and LC3B immunostaining, myelin internode analysis","journal":"bioRxiv (preprint)","confidence":"Low","confidence_rationale":"Tier 3 — preprint, single study, novel cell model; functional phenotype without full pathway placement","pmids":[],"is_preprint":true},{"year":2025,"finding":"Recombinant murine GALC administered to GALC-deficient (twitcher) primary cells restores autophagic function at physiological dose (LC3 and p62 markers normalized), while supra-physiological GALC causes autophagy impairment and decreased viability, demonstrating dose-dependent lysosomal-autophagic pathway interaction.","method":"Enzyme replacement in vitro, LC3 and p62 immunoblotting, cell viability assay","journal":"Advanced Biology","confidence":"Low","confidence_rationale":"Tier 3 — single in vitro study with functional autophagy readout; limited mechanistic detail","pmids":["40590240"],"is_preprint":false}],"current_model":"GALC encodes a lysosomal β-galactocerebrosidase that forms a heterotetrameric complex with the saposin SapA—with a channel connecting the enzyme active site to SapA's hydrophobic cavity—to hydrolyze the polar galactosyl headgroups of galactosylceramide and galactosylsphingosine (psychosine) from their ceramide tails; deficiency causes psychosine accumulation and autonomous demyelination in myelin-forming cells as well as galactosylceramide storage in macrophages that drives secondary neuroinflammation, while GALC activity level in lysosomes (determined by proper lysosomal trafficking and processing of the enzyme) is the key determinant of disease onset and severity."},"narrative":{"teleology":[{"year":1995,"claim":"Identification of GALC as the gene encoding galactosylceramidase established the molecular identity of the lysosomal enzyme responsible for galactosylceramide and psychosine catabolism.","evidence":"Biochemical purification from human urine/brain, cDNA cloning, and gene structure determination","pmids":["7601472"],"confidence":"High","gaps":["Three-dimensional structure unknown","Mechanism of substrate presentation to the soluble enzyme not addressed","Determinants of enzyme trafficking to lysosomes not characterized"]},{"year":1996,"claim":"Demonstrating that GALC is secreted and recaptured via mannose-6-phosphate receptors for lysosomal delivery established the cell biology of GALC trafficking and the basis for cross-correction therapy.","evidence":"Retroviral transduction of fibroblasts with secretion/uptake assays and mannose-6-phosphate receptor inhibition","pmids":["8812733"],"confidence":"High","gaps":["Efficiency of cross-correction in vivo not tested","Post-translational processing steps for lysosomal maturation not defined"]},{"year":1997,"claim":"Characterization of the GALC promoter as a GC-rich, TATA-less region with Sp1 sites and flanking inhibitory elements explained the constitutively low expression of GALC across cell types; splicing mutations (IVS6+5G>A) causing exon skipping and NMD were established as a disease mechanism.","evidence":"CAT reporter deletion constructs for promoter; mini-gene transfection for splice mutation","pmids":["9441867","10464649"],"confidence":"Medium","gaps":["In vivo promoter regulation and tissue-specific modulators not addressed","No systematic survey of splicing mutations"]},{"year":2006,"claim":"Establishing that the twitcher nonsense mutation triggers NMD of GALC mRNA, and that lentiviral GALC localizes to lysosomes in neural cells with functional cross-correction, defined both a mRNA-level disease mechanism and a gene therapy rationale.","evidence":"NMD inhibitor rescue in twitcher Schwann cells; lentiviral transduction with lysosomal immunostaining and conditioned medium correction","pmids":["16759875","16732552"],"confidence":"High","gaps":["In vivo cross-correction efficiency in CNS not determined","Relative contributions of NMD vs. protein instability for other mutations unknown"]},{"year":2013,"claim":"The GALCtwi-5J missense mouse model showed that loss of GALC catalytic activity with normal precursor levels leads to psychosine accumulation and PNS-predominant dysmyelination, distinguishing a primary dysmyelination mechanism from secondary inflammatory demyelination.","evidence":"E130K missense knock-in mouse with enzyme activity, psychosine quantification, and neuropathology","pmids":["23620143"],"confidence":"Medium","gaps":["Why CNS myelin is relatively spared in this model not explained","Whether psychosine toxicity is direct or involves intermediate effectors unresolved"]},{"year":2016,"claim":"Resolving the genotype-phenotype puzzle, subcellular fractionation demonstrated that lysosomal (not total cellular) GALC activity determines disease severity, with infantile mutations showing defective lysosomal trafficking and cis-polymorphisms modulating enzyme processing.","evidence":"Lysosomal fractionation, enzyme activity in lysosomes vs. whole-cell lysates, trafficking analysis of multiple GALC mutants","pmids":["26865610"],"confidence":"High","gaps":["Structural basis for trafficking defects not defined","How cis-polymorphisms mechanistically alter processing not fully resolved"]},{"year":2017,"claim":"Demonstrating that GALC haploinsufficiency impairs microglial phagocytosis and remyelination after demyelination revealed a non-cell-autonomous role for GALC in myelin repair beyond its canonical catabolic function.","evidence":"Cuprizone demyelination in GALC+/- mice with histology, Trem2 analysis, and pharmacological rescue","pmids":["28575206"],"confidence":"Medium","gaps":["Whether Trem2 reduction is a direct consequence of lipid substrate accumulation or an indirect effect is unclear","Relevance to human heterozygous carriers not tested"]},{"year":2018,"claim":"The crystal structure of the GALC–SapA complex revealed a heterotetrameric architecture with a channel connecting the active site to SapA's hydrophobic cavity, providing the structural basis for how a soluble hydrolase accesses lipid substrates embedded in membranes.","evidence":"X-ray crystallography with functional validation","pmids":["29323104"],"confidence":"High","gaps":["How the complex assembles on lysosomal membranes in situ not resolved","Structural consequences of disease-causing mutations on the GALC–SapA interface not systematically mapped"]},{"year":2020,"claim":"Cell-type-specific GALC ablation in mice dissected two independent disease mechanisms: autonomous psychosine-driven demyelination in Schwann cells and galactosylceramide-driven globoid cell transformation in macrophages causing secondary neuroinflammation.","evidence":"Cell-type-specific GALC-deficient mouse model with hematopoietic stem cell transplantation","pmids":["32375064"],"confidence":"High","gaps":["Relative contribution of each mechanism to human disease progression not quantified","Why cross-correction is inefficient in vivo not mechanistically explained"]},{"year":2025,"claim":"A zebrafish GALC model revealed lactosylceramide as a neuroinflammatory metabolite accumulating upon GALC loss, broadening the pathogenic lipid repertoire beyond psychosine and galactosylceramide.","evidence":"CRISPR/Cas9 galcb knockout zebrafish with targeted lipidomics and intraventricular LacCer injection","pmids":["40305757"],"confidence":"Medium","gaps":["Whether LacCer accumulation occurs in mammalian Krabbe models not established","Enzymatic basis for LacCer as a GALC substrate vs. secondary metabolic effect unclear"]},{"year":null,"claim":"Key unresolved questions include the structural basis for how disease-causing mutations differentially affect lysosomal trafficking vs. catalytic activity, whether lactosylceramide accumulation contributes to human Krabbe pathogenesis, and the mechanism underlying inefficient in vivo cross-correction of GALC.","evidence":"","pmids":[],"confidence":"High","gaps":["No systematic structure-function mapping of mutations onto GALC-SapA complex","Lactosylceramide role in mammalian models not tested","Determinants of in vivo cross-correction efficiency unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,3,11]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[1,2,3,12]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,4,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,4,11]}],"complexes":["GALC-SapA heterotetramer"],"partners":["PSAP"],"other_free_text":[]},"mechanistic_narrative":"GALC encodes galactosylceramidase (EC 3.2.1.46), a lysosomal hydrolase that cleaves the galactosyl headgroup from galactosylceramide and galactosylsphingosine (psychosine), functioning as a heterotetrameric complex with the saposin SapA via a channel connecting the enzyme active site to SapA's hydrophobic cavity [PMID:29323104, PMID:7601472]. The enzyme is trafficked to lysosomes through mannose-6-phosphate receptor–mediated uptake and can be secreted and cross-corrected between cells, with lysosomal GALC activity—determined by proper trafficking and processing—serving as the key determinant of disease onset and severity [PMID:8812733, PMID:26865610]. Loss-of-function mutations cause Krabbe disease (globoid cell leukodystrophy), in which psychosine accumulation drives autonomous demyelination in myelin-forming cells while galactosylceramide storage in macrophages triggers secondary neuroinflammation through globoid cell formation, representing two distinct pathogenic mechanisms [PMID:32375064, PMID:23620143]. GALC haploinsufficiency also impairs microglial phagocytic clearance of myelin debris and remyelination capacity [PMID:28575206]."},"prefetch_data":{"uniprot":{"accession":"P54803","full_name":"Galactocerebrosidase","aliases":["Galactocerebroside beta-galactosidase","Galactosylceramidase","Galactosylceramide beta-galactosidase"],"length_aa":685,"mass_kda":77.1,"function":"Hydrolyzes the galactose ester bonds of glycolipids such as galactosylceramide and galactosylsphingosine (PubMed:8281145, PubMed:8399327). Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon (PubMed:8281145, PubMed:8399327)","subcellular_location":"Lysosome","url":"https://www.uniprot.org/uniprotkb/P54803/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GALC","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GALC","total_profiled":1310},"omim":[{"mim_id":"621302","title":"NEURODEVELOPMENTAL DISORDER WITH SEIZURES AND JOINT LAXITY; NEDSJL","url":"https://www.omim.org/entry/621302"},{"mim_id":"613468","title":"N-ACYLSPHINGOSINE AMIDOHYDROLASE 1; ASAH1","url":"https://www.omim.org/entry/613468"},{"mim_id":"611722","title":"KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY; KRBSAPA","url":"https://www.omim.org/entry/611722"},{"mim_id":"611458","title":"GALACTOSIDASE, BETA-1; GLB1","url":"https://www.omim.org/entry/611458"},{"mim_id":"606897","title":"LYSOSOMAL TRAFFICKING REGULATOR; LYST","url":"https://www.omim.org/entry/606897"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GALC"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P54803","domains":[{"cath_id":"3.20.20.80","chopping":"56-276_292-326","consensus_level":"high","plddt":98.6054,"start":56,"end":326},{"cath_id":"2.60.120.560","chopping":"488-683","consensus_level":"high","plddt":97.4219,"start":488,"end":683}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P54803","model_url":"https://alphafold.ebi.ac.uk/files/AF-P54803-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P54803-F1-predicted_aligned_error_v6.png","plddt_mean":94.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GALC","jax_strain_url":"https://www.jax.org/strain/search?query=GALC"},"sequence":{"accession":"P54803","fasta_url":"https://rest.uniprot.org/uniprotkb/P54803.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P54803/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P54803"}},"corpus_meta":[{"pmid":"2223090","id":"PMC_2223090","title":"Two proliferative stages of the oligodendrocyte lineage (A2B5+O4- and O4+GalC-) under different mitogenic control.","date":"1990","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/2223090","citation_count":254,"is_preprint":false},{"pmid":"8405684","id":"PMC_8405684","title":"Glial cell mitogens bFGF and PDGF differentially regulate development of O4+GalC- oligodendrocyte progenitors.","date":"1993","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8405684","citation_count":157,"is_preprint":false},{"pmid":"20886637","id":"PMC_20886637","title":"Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20886637","citation_count":98,"is_preprint":false},{"pmid":"7581365","id":"PMC_7581365","title":"A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7581365","citation_count":98,"is_preprint":false},{"pmid":"7601472","id":"PMC_7601472","title":"Structure and organization of the human galactocerebrosidase (GALC) gene.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7601472","citation_count":81,"is_preprint":false},{"pmid":"8634707","id":"PMC_8634707","title":"Characterization of the large deletion in the GALC gene found in patients with Krabbe disease.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8634707","citation_count":74,"is_preprint":false},{"pmid":"7875381","id":"PMC_7875381","title":"Oligodendroblasts distinguished from O-2A glial progenitors by surface phenotype (O4+GalC-) and response to cytokines using signal transducer LIFR beta.","date":"1995","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7875381","citation_count":74,"is_preprint":false},{"pmid":"8661004","id":"PMC_8661004","title":"Cloning of the canine GALC cDNA and identification of the mutation causing globoid cell leukodystrophy in West Highland White and Cairn terriers.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8661004","citation_count":74,"is_preprint":false},{"pmid":"9192853","id":"PMC_9192853","title":"Characterization of the rhesus monkey galactocerebrosidase (GALC) cDNA and gene and identification of the mutation causing globoid cell leukodystrophy (Krabbe disease) in this primate.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9192853","citation_count":60,"is_preprint":false},{"pmid":"16607461","id":"PMC_16607461","title":"Six novel mutations detected in the GALC gene in 17 Japanese patients with Krabbe disease, and new genotype-phenotype correlation.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16607461","citation_count":58,"is_preprint":false},{"pmid":"32375064","id":"PMC_32375064","title":"Macrophages Expressing GALC Improve Peripheral Krabbe Disease by a Mechanism Independent of Cross-Correction.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/32375064","citation_count":57,"is_preprint":false},{"pmid":"26329589","id":"PMC_26329589","title":"Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.","date":"2015","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26329589","citation_count":53,"is_preprint":false},{"pmid":"8687180","id":"PMC_8687180","title":"Multiple mutations in the GALC gene in a patient with adult-onset Krabbe disease.","date":"1996","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/8687180","citation_count":52,"is_preprint":false},{"pmid":"23620143","id":"PMC_23620143","title":"Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23620143","citation_count":49,"is_preprint":false},{"pmid":"27638599","id":"PMC_27638599","title":"Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant.","date":"2016","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/27638599","citation_count":46,"is_preprint":false},{"pmid":"29323104","id":"PMC_29323104","title":"The mechanism of glycosphingolipid degradation revealed by a GALC-SapA complex structure.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29323104","citation_count":45,"is_preprint":false},{"pmid":"25533112","id":"PMC_25533112","title":"Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.","date":"2014","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25533112","citation_count":43,"is_preprint":false},{"pmid":"8423632","id":"PMC_8423632","title":"Transient reversion of O4+ GalC- oligodendrocyte progenitor development in response to the phorbol ester TPA.","date":"1993","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/8423632","citation_count":41,"is_preprint":false},{"pmid":"7544324","id":"PMC_7544324","title":"Elevated intracellular levels of cAMP induce olfactory ensheathing cells to express GAL-C and GFAP but not MBP.","date":"1995","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/7544324","citation_count":41,"is_preprint":false},{"pmid":"26865610","id":"PMC_26865610","title":"Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26865610","citation_count":38,"is_preprint":false},{"pmid":"8812733","id":"PMC_8812733","title":"Retroviral vector-mediated transfer of the galactocerebrosidase (GALC) cDNA leads to overexpression and transfer of GALC activity to neighboring cells.","date":"1996","source":"Biochemical and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8812733","citation_count":38,"is_preprint":false},{"pmid":"17579360","id":"PMC_17579360","title":"A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region.","date":"2007","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17579360","citation_count":36,"is_preprint":false},{"pmid":"8162701","id":"PMC_8162701","title":"Regional mapping of the human galactocerebrosidase gene (GALC) to 14q31 by in situ hybridization.","date":"1994","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8162701","citation_count":36,"is_preprint":false},{"pmid":"22073273","id":"PMC_22073273","title":"GALC deletions increase the risk of primary open-angle glaucoma: the role of Mendelian variants in complex disease.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22073273","citation_count":34,"is_preprint":false},{"pmid":"16732552","id":"PMC_16732552","title":"Design and optimization of lentiviral vectors for transfer of GALC expression in Twitcher brain.","date":"2006","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16732552","citation_count":33,"is_preprint":false},{"pmid":"11814461","id":"PMC_11814461","title":"Residual galactosylsphingosine (psychosine) beta-galactosidase activities and associated GALC mutations in late and very late onset Krabbe disease.","date":"2002","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11814461","citation_count":31,"is_preprint":false},{"pmid":"28575206","id":"PMC_28575206","title":"Heterozygote galactocerebrosidase (GALC) mutants have reduced remyelination and impaired myelin debris clearance following demyelinating injury.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28575206","citation_count":29,"is_preprint":false},{"pmid":"1382941","id":"PMC_1382941","title":"Stage specific, (O4+GalC-) isolated oligodendrocyte progenitors produce MBP+ myelin in vivo.","date":"1992","source":"Developmental neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/1382941","citation_count":29,"is_preprint":false},{"pmid":"25101718","id":"PMC_25101718","title":"IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease.","date":"2015","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25101718","citation_count":27,"is_preprint":false},{"pmid":"16759875","id":"PMC_16759875","title":"Suppression of galactosylceramidase (GALC) expression in the twitcher mouse model of globoid cell leukodystrophy (GLD) is caused by nonsense-mediated mRNA decay (NMD).","date":"2006","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/16759875","citation_count":27,"is_preprint":false},{"pmid":"9266397","id":"PMC_9266397","title":"Prevalent mutations in the GALC gene of patients with Krabbe disease of Dutch and other European origin.","date":"1997","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/9266397","citation_count":27,"is_preprint":false},{"pmid":"36370000","id":"PMC_36370000","title":"GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson's disease.","date":"2023","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36370000","citation_count":26,"is_preprint":false},{"pmid":"26108143","id":"PMC_26108143","title":"Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26108143","citation_count":26,"is_preprint":false},{"pmid":"8250040","id":"PMC_8250040","title":"Localization of the Krabbe disease gene (GALC) on chromosome 14 by multipoint linkage analysis.","date":"1993","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8250040","citation_count":22,"is_preprint":false},{"pmid":"9972877","id":"PMC_9972877","title":"Transduction of cultured oligodendrocytes from normal and twitcher mice by a retroviral vector containing human galactocerebrosidase (GALC) cDNA.","date":"1999","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/9972877","citation_count":22,"is_preprint":false},{"pmid":"23462331","id":"PMC_23462331","title":"Four novel GALC gene mutations in two Chinese patients with Krabbe disease.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23462331","citation_count":17,"is_preprint":false},{"pmid":"33178108","id":"PMC_33178108","title":"Pathogenic Variants in GALC Gene Correlate With Late Onset Krabbe Disease and Vision Loss: Case Series and Review of Literature.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33178108","citation_count":17,"is_preprint":false},{"pmid":"33842284","id":"PMC_33842284","title":"Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?","date":"2021","source":"BioImpacts : BI","url":"https://pubmed.ncbi.nlm.nih.gov/33842284","citation_count":15,"is_preprint":false},{"pmid":"22959700","id":"PMC_22959700","title":"Isolated pyramidal tract impairment in the central nervous system of adult-onset Krabbe disease with novel mutations in the GALC gene.","date":"2012","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/22959700","citation_count":15,"is_preprint":false},{"pmid":"15781194","id":"PMC_15781194","title":"GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo.","date":"2005","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15781194","citation_count":15,"is_preprint":false},{"pmid":"32318333","id":"PMC_32318333","title":"GALC Triggers Tumorigenicity of Colorectal Cancer via Senescent Fibroblasts.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32318333","citation_count":14,"is_preprint":false},{"pmid":"32677356","id":"PMC_32677356","title":"Adult-onset Krabbe disease due to a homozygous GALC mutation without abnormal signals on an MRI in a consanguineous family: A case report.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32677356","citation_count":13,"is_preprint":false},{"pmid":"23276707","id":"PMC_23276707","title":"A novel homozygous GALC mutation: very early onset and rapidly progressive Krabbe disease.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23276707","citation_count":11,"is_preprint":false},{"pmid":"29136295","id":"PMC_29136295","title":"Genomewide association study identifies GALC as susceptibility gene for mucous membrane pemphigoid.","date":"2017","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29136295","citation_count":11,"is_preprint":false},{"pmid":"10464649","id":"PMC_10464649","title":"Characterization of the GALC gene in three Japanese patients with adult-onset Krabbe disease.","date":"1997","source":"Genetic testing","url":"https://pubmed.ncbi.nlm.nih.gov/10464649","citation_count":10,"is_preprint":false},{"pmid":"35013804","id":"PMC_35013804","title":"A novel compound heterozygous mutation in GALC associated with adult-onset Krabbe disease: case report and literature review.","date":"2022","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/35013804","citation_count":9,"is_preprint":false},{"pmid":"32186243","id":"PMC_32186243","title":"Molecular dynamics simulations to decipher the structural and functional consequences of pathogenic missense mutations in the galactosylceramidase (GALC) protein causing Krabbe's disease.","date":"2020","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/32186243","citation_count":8,"is_preprint":false},{"pmid":"9441867","id":"PMC_9441867","title":"Analysis of the 5' flanking region of the human galactocerebrosidase (GALC) gene.","date":"1997","source":"Biochemical and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9441867","citation_count":8,"is_preprint":false},{"pmid":"37628569","id":"PMC_37628569","title":"Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37628569","citation_count":7,"is_preprint":false},{"pmid":"35654103","id":"PMC_35654103","title":"A novel GALC gene mutation associated with adult-onset Krabbe disease: a case report.","date":"2022","source":"Neurocase","url":"https://pubmed.ncbi.nlm.nih.gov/35654103","citation_count":7,"is_preprint":false},{"pmid":"37111381","id":"PMC_37111381","title":"rAAV2-Mediated Restoration of GALC in Neural Stem Cells from Krabbe Patient-Derived iPSCs.","date":"2023","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37111381","citation_count":7,"is_preprint":false},{"pmid":"26567009","id":"PMC_26567009","title":"Clinical and molecular report of novel GALC mutations in Moroccan patient with Krabbe disease: case report.","date":"2015","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/26567009","citation_count":7,"is_preprint":false},{"pmid":"32973651","id":"PMC_32973651","title":"Novel GALC Mutations Cause Adult-Onset Krabbe Disease With Myelopathy in Two Chinese Families: Case Reports and Literature Review.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32973651","citation_count":7,"is_preprint":false},{"pmid":"31185936","id":"PMC_31185936","title":"GALC mutations in Chinese patients with late-onset Krabbe disease: a case report.","date":"2019","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31185936","citation_count":7,"is_preprint":false},{"pmid":"38515343","id":"PMC_38515343","title":"Clinical feature, GALC variant spectrum, and genotype-phenotype correlation in Korean Krabbe disease patients: Multicenter experience over 13 years.","date":"2024","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38515343","citation_count":6,"is_preprint":false},{"pmid":"33424556","id":"PMC_33424556","title":"AAV-Mediated GALC Gene Therapy Rescues Alpha-Synucleinopathy in the Spinal Cord of a Leukodystrophic Lysosomal Storage Disease Mouse Model.","date":"2020","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33424556","citation_count":6,"is_preprint":false},{"pmid":"28109651","id":"PMC_28109651","title":"Late onset Krabbe disease due to the new GALC p.Ala543Pro mutation, with intriguingly high residual GALC activity in vitro.","date":"2017","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/28109651","citation_count":6,"is_preprint":false},{"pmid":"40391866","id":"PMC_40391866","title":"High Prevalence of GALC Gene Variants in Adults With Neurodegenerative Conditions.","date":"2025","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40391866","citation_count":5,"is_preprint":false},{"pmid":"26178533","id":"PMC_26178533","title":"GALC gene is downregulated by promoter hypermethylation in Epstein-Barr virus-associated nasopharyngeal carcinoma.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26178533","citation_count":5,"is_preprint":false},{"pmid":"32304783","id":"PMC_32304783","title":"Allele frequency analysis of GALC gene causing Krabbe disease in human and its codon usage.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32304783","citation_count":4,"is_preprint":false},{"pmid":"36551902","id":"PMC_36551902","title":"Reliable and Fast Genotyping Protocol for Galactosylceramidase (Galc) in the Twitcher (Twi) Mouse.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36551902","citation_count":4,"is_preprint":false},{"pmid":"38762762","id":"PMC_38762762","title":"Splicing mutations of GALC in adult patient with adult-onset Krabbe disease: case report and review of literature.","date":"2024","source":"Neurocase","url":"https://pubmed.ncbi.nlm.nih.gov/38762762","citation_count":4,"is_preprint":false},{"pmid":"27442402","id":"PMC_27442402","title":"Compound Galactosylceramidase Gene (GALC) Heterozygosity in a Boy with Infantile Krabbe Disease (KD).","date":"2015","source":"Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)","url":"https://pubmed.ncbi.nlm.nih.gov/27442402","citation_count":4,"is_preprint":false},{"pmid":"22704718","id":"PMC_22704718","title":"Array CGH improves detection of mutations in the GALC gene associated with Krabbe disease.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22704718","citation_count":4,"is_preprint":false},{"pmid":"30323943","id":"PMC_30323943","title":"Exonic deletions in GALC are frequent in Japanese globoid-cell leukodystrophy patients.","date":"2018","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/30323943","citation_count":4,"is_preprint":false},{"pmid":"36270068","id":"PMC_36270068","title":"Production and characterization of human induced pluripotent stem cell line (PUMCi002-A) from a Krabbe patient related control to study disease mechanisms associated with GALC mutation.","date":"2022","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36270068","citation_count":4,"is_preprint":false},{"pmid":"40305757","id":"PMC_40305757","title":"Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40305757","citation_count":3,"is_preprint":false},{"pmid":"40590240","id":"PMC_40590240","title":"Investigating the Cellular Effects of GALC Dosing in Enzyme Replacement Therapy for Krabbe Disease Supports the Role of Nanomedicine.","date":"2025","source":"Advanced biology","url":"https://pubmed.ncbi.nlm.nih.gov/40590240","citation_count":3,"is_preprint":false},{"pmid":"34765479","id":"PMC_34765479","title":"Compound heterozygous pathogenic variants in the GALC gene cause infant-onset Krabbe disease.","date":"2021","source":"Translational pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34765479","citation_count":2,"is_preprint":false},{"pmid":"40692539","id":"PMC_40692539","title":"Amelioration of Inflammation and Metabolic Blockage in GALC Deficient Mice After Enzyme Replacement Therapy via Extracellular Vesicles.","date":"2025","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40692539","citation_count":1,"is_preprint":false},{"pmid":"41086929","id":"PMC_41086929","title":"Beyond Krabbe disease, the intriguing connection of galactocerebrosidase (GALC) with nervous system illness: A novel risk factor?","date":"2025","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41086929","citation_count":1,"is_preprint":false},{"pmid":"30209698","id":"PMC_30209698","title":"A novel homozygous GALC variant has been associated with Krabbe disease in a consanguineous family.","date":"2018","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/30209698","citation_count":1,"is_preprint":false},{"pmid":"39464077","id":"PMC_39464077","title":"Expression study of Krabbe Disease GALC missense variants - Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39464077","citation_count":1,"is_preprint":false},{"pmid":"40943566","id":"PMC_40943566","title":"Molecular Characterization of the GALC Mutation Thr112Ala Causing Krabbe Disease.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40943566","citation_count":0,"is_preprint":false},{"pmid":"41463122","id":"PMC_41463122","title":"Abnormal Splicing of GALC Transcripts Underlies Unusual Cases of Krabbe Disease.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/41463122","citation_count":0,"is_preprint":false},{"pmid":"42026681","id":"PMC_42026681","title":"In vivo adenine base editing of mutant Galc gene ameliorates Krabbe disease progression.","date":"2026","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/42026681","citation_count":0,"is_preprint":false},{"pmid":"10424145","id":"PMC_10424145","title":"[A case of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome with positive anti-galactocerebroside (Gal-C) IgM antibody].","date":"1999","source":"Rinsho shinkeigaku = Clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10424145","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.10.17.618938","title":"Expression study of Krabbe Disease<i>GALC</i>missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels","date":"2024-10-17","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.17.618938","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.16.623962","title":"Haploinsufficiency of lysosomal enzyme genes in Alzheimer’s disease","date":"2024-11-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.16.623962","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.19.604372","title":"Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease","date":"2024-07-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.19.604372","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":40261,"output_tokens":4316,"usd":0.092761},"stage2":{"model":"claude-opus-4-6","input_tokens":7792,"output_tokens":2550,"usd":0.154065},"total_usd":0.246826,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"GALC forms a heterotetrameric complex with the saposin SapA to degrade glycosphingolipids: crystal structure of the GALC-SapA complex reveals an open channel connecting the enzyme active site to the SapA hydrophobic cavity, explaining how the soluble hydrolase cleaves the polar glycosyl headgroups of galactosylceramide from their hydrophobic ceramide tails.\",\n      \"method\": \"Crystal structure determination (structural biology) with functional validation\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mechanistic interpretation of substrate channeling; single rigorous paper with structural and functional detail\",\n      \"pmids\": [\"29323104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GALC catalyzes lysosomal hydrolysis of galactosylceramide (galactocerebroside) and galactosylsphingosine (psychosine) as primary substrates; the enzyme is a lysosomal hydrolase (EC 3.2.1.46) purified from human urine and brain, and the GALC gene encodes 17 exons spanning ~60 kb.\",\n      \"method\": \"Biochemical purification, cDNA cloning, gene structure determination\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic characterization and gene structure; replicated across multiple studies\",\n      \"pmids\": [\"7601472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GALC expressed via retroviral vector in fibroblasts is secreted into the media and taken up by neighboring untransduced cells; uptake is partially mannose-6-phosphate receptor-mediated, and internalized GALC localizes to lysosomes where it metabolizes galactosylceramide.\",\n      \"method\": \"Retroviral transduction, secretion assay, mannose-6-phosphate receptor inhibition, radiolabeled substrate metabolism in lysosomes\",\n      \"journal\": \"Biochemical and Molecular Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution of enzyme activity in recipient cells, subcellular localization confirmed, receptor pathway identified with direct inhibition\",\n      \"pmids\": [\"8812733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Infantile-onset GALC mutants show reduced trafficking to lysosomes and reduced processing compared to later-onset mutants; lysosomal GALC activity (not total cell lysate activity) correlates with disease severity, and cis-polymorphisms modulate lysosomal trafficking and processing of GALC.\",\n      \"method\": \"Subcellular fractionation to isolate lysosomal fraction, enzyme activity assay in lysosomes vs. whole-cell lysates, trafficking analysis of mutant GALC proteins\",\n      \"journal\": \"The Journal of Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct lysosomal fractionation with functional consequence, multiple mutants tested with orthogonal activity and trafficking assays\",\n      \"pmids\": [\"26865610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GALC is required for macrophage degradation of myelin-derived galactosylceramide; GALC-deficient macrophages accumulate galactosylceramide and transform into globoid cells, causing secondary neuroinflammation independent of psychosine-induced demyelination. Cross-correction of GALC does not occur efficiently in vivo, and Schwann cells autonomously produce psychosine.\",\n      \"method\": \"Novel GLD mouse model with cell-type-specific GALC deficiency, in vivo macrophage exposure to galactosylceramide, hematopoietic stem cell transplantation experiments\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic in vivo model with defined cellular phenotype, multiple orthogonal experiments demonstrating two distinct disease mechanisms\",\n      \"pmids\": [\"32375064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The twitcher mouse nonsense mutation (W339X) in GALC causes nonsense-mediated mRNA decay (NMD) of GALC transcripts, resulting in undetectable truncated protein; NMD inhibitors (anisomycin, emetine, puromycin) restore GALC transcript levels in twitcher-derived Schwann cells.\",\n      \"method\": \"Western blot, quantitative RT-PCR, NMD inhibitor treatment in twitcher Schwann cell line (TwS1)\",\n      \"journal\": \"Neurobiology of Disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors tested with quantitative mRNA measurements, mechanistically defining the cause of absent GALC protein\",\n      \"pmids\": [\"16759875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The 5' flanking region of the human GALC gene contains a GC-rich promoter with Sp1 binding sites but no TATA or CAAT boxes; a construct from nucleotides -176 to -24 has strongest promoter activity, with inhibitory sequences upstream of the promoter and within the first 234 nucleotides of intron 1, explaining low GALC protein levels across all cell types.\",\n      \"method\": \"Chloramphenicol acetyltransferase (CAT) reporter assay with deletion constructs\",\n      \"journal\": \"Biochemical and Molecular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter gene assay directly measuring promoter activity; single study\",\n      \"pmids\": [\"9441867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Expression studies in COS-1 cells confirmed that the A473C transversion (Y158S) in canine GALC is the disease-causing mutation in West Highland White and Cairn terriers with globoid cell leukodystrophy, while the C1915T change (P639S) is not causative.\",\n      \"method\": \"COS-1 cell expression system with site-specific mutation, enzyme activity assay\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct expression and enzyme activity measurement distinguishing disease-causing from non-causative mutation\",\n      \"pmids\": [\"8661004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The GALC p.Gly41Ser missense mutation abolishes galactocerebrosidase catalytic activity, as confirmed by expression studies, and causes late-onset Krabbe disease as a founder mutation in the Catania region of Sicily.\",\n      \"method\": \"Expression studies with enzyme activity assay\",\n      \"journal\": \"Human Mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzyme activity measurement in expression system; single study\",\n      \"pmids\": [\"17579360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"An intronic IVS6+5G>A mutation in GALC causes exon 6 skipping, demonstrated by GALC mini-gene transfection experiments; the resulting transcript from the nonsense mutation allele undergoes rapid degradation consistent with NMD.\",\n      \"method\": \"Mini-gene transfection, mRNA analysis\",\n      \"journal\": \"Genetic Testing\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mini-gene functional splicing assay; single study\",\n      \"pmids\": [\"10464649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"N-octyl-4-epi-β-valienamine (NOEV) acts as a pharmacological chaperone for mutant GALC: it inhibits GALC activity in cell lysates, stabilizes GALC under heat denaturation, binds to the active site (structural modeling), and enhances maturation of GALC precursor to its mature active form, increasing activity of late-onset mutant GALC in COS1 cells and patient fibroblasts.\",\n      \"method\": \"Enzyme activity assay, heat denaturation protection assay, in vitro chaperone treatment in COS1 cells and patient fibroblasts, structural modeling\",\n      \"journal\": \"Journal of Human Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro assays; single lab, chaperone active-site binding defined\",\n      \"pmids\": [\"26108143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The GALC E130K missense mutation causes loss of enzymatic activity despite normal precursor protein levels; the GALCtwi-5J mouse model shows that loss of GALC activity leads to psychosine accumulation and severe PNS hypomyelination/dysmyelination with preserved CNS myelin, suggesting primary dysmyelination mechanism distinct from the twitcher model.\",\n      \"method\": \"Mouse model with missense mutation, enzyme activity assay, neuropathology, psychosine measurement\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function mouse model with specific cellular and biochemical phenotype; single study\",\n      \"pmids\": [\"23620143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Lentiviral vector-expressed GALC accumulates in lysosomes of transduced neural cells (neurons, oligodendrocytes, astrocytes) and is also secreted into the extracellular medium; conditioned GALC medium corrects enzyme deficiency in non-transduced twitcher glial cultures.\",\n      \"method\": \"Lentiviral transduction, subcellular localization by immunostaining, conditioned medium cross-correction assay\",\n      \"journal\": \"The Journal of Gene Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization to lysosome with cross-correction functional assay; single study\",\n      \"pmids\": [\"16732552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Heterozygous GALC mutant mice show reduced myelin debris clearance and diminished remyelination after cuprizone-induced demyelination; microglial phagocytic response and Trem2 elevation are markedly reduced in GALC+/- animals, and these defects can be corrected in vitro by NKH-477 treatment.\",\n      \"method\": \"Cuprizone demyelination model in GALC+/- mice, histology, Trem2 analysis, in vitro pharmacological rescue\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined loss-of-function model with specific microglial/remyelination phenotype; single lab with pharmacological rescue validation\",\n      \"pmids\": [\"28575206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In a zebrafish GALC model, galcb knockout (not galca) dramatically reduces total GALC activity; galcb KO zebrafish accumulate lactosylceramide (LacCer) rather than psychosine in brain, and intraventricular LacCer injection induces neuroinflammatory markers and macrophage infiltration, implicating LacCer as a neuroinflammatory metabolite in GALC deficiency.\",\n      \"method\": \"CRISPR/Cas9 knockout in zebrafish, GALC activity assay, targeted lipidomics, intraventricular LacCer injection, immunohistochemistry, gene expression analysis\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ortholog model with multiple orthogonal methods; novel mechanistic finding about LacCer role, single study\",\n      \"pmids\": [\"40305757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Systematic expression of 31 clinically-relevant GALC missense variants in a GALC-knockout human oligodendrocytic cell line shows that infantile-onset variants retain <2% of wild-type activity, later-onset variants retain up to 7%, residual GALC activity correlates with mature lysosomal GALC protein levels (Pearson r=0.93), and many low-activity variants have defective lysosomal trafficking (mis-trafficking) while retaining secretion capacity.\",\n      \"method\": \"CRISPR-Cas9 GALC knockout cell line, transient expression assays, enzyme activity assay, lysosomal GALC protein quantification, secretion assays, psychosine measurement\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic quantitative functional analysis in relevant human cell model with multiple orthogonal methods; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"39464077\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GALC knockout by CRISPR-Cas9 in neuronal cell models does not lead to alpha-synuclein accumulation, suggesting that increased rather than reduced galactosylceramidase activity may be associated with Parkinson's disease; structural analysis indicates the common variant p.I562T leads to improper GALC maturation affecting activity.\",\n      \"method\": \"CRISPR-Cas9 knockout, alpha-synuclein immunoassay, in silico structural analysis, GBA activity assay\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct KO experiment with specific phenotypic readout; single study\",\n      \"pmids\": [\"36370000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"iPSC-derived microglia from Krabbe patients form globoid cells when fed galactosylceramide (GalCer), with accumulation of autophagy proteins and LAMP1 reduction, demonstrating that GalCer loading triggers lysosomal dysfunction and globoid cell transformation; Krabbe myelinating organoids show early myelination defects without autophagy or mTOR pathway dysregulation.\",\n      \"method\": \"iPSC-derived microglia and myelinating organoids, GalCer feeding assay, LAMP1 and LC3B immunostaining, myelin internode analysis\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — preprint, single study, novel cell model; functional phenotype without full pathway placement\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Recombinant murine GALC administered to GALC-deficient (twitcher) primary cells restores autophagic function at physiological dose (LC3 and p62 markers normalized), while supra-physiological GALC causes autophagy impairment and decreased viability, demonstrating dose-dependent lysosomal-autophagic pathway interaction.\",\n      \"method\": \"Enzyme replacement in vitro, LC3 and p62 immunoblotting, cell viability assay\",\n      \"journal\": \"Advanced Biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single in vitro study with functional autophagy readout; limited mechanistic detail\",\n      \"pmids\": [\"40590240\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GALC encodes a lysosomal β-galactocerebrosidase that forms a heterotetrameric complex with the saposin SapA—with a channel connecting the enzyme active site to SapA's hydrophobic cavity—to hydrolyze the polar galactosyl headgroups of galactosylceramide and galactosylsphingosine (psychosine) from their ceramide tails; deficiency causes psychosine accumulation and autonomous demyelination in myelin-forming cells as well as galactosylceramide storage in macrophages that drives secondary neuroinflammation, while GALC activity level in lysosomes (determined by proper lysosomal trafficking and processing of the enzyme) is the key determinant of disease onset and severity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GALC encodes galactosylceramidase (EC 3.2.1.46), a lysosomal hydrolase that cleaves the galactosyl headgroup from galactosylceramide and galactosylsphingosine (psychosine), functioning as a heterotetrameric complex with the saposin SapA via a channel connecting the enzyme active site to SapA's hydrophobic cavity [PMID:29323104, PMID:7601472]. The enzyme is trafficked to lysosomes through mannose-6-phosphate receptor–mediated uptake and can be secreted and cross-corrected between cells, with lysosomal GALC activity—determined by proper trafficking and processing—serving as the key determinant of disease onset and severity [PMID:8812733, PMID:26865610]. Loss-of-function mutations cause Krabbe disease (globoid cell leukodystrophy), in which psychosine accumulation drives autonomous demyelination in myelin-forming cells while galactosylceramide storage in macrophages triggers secondary neuroinflammation through globoid cell formation, representing two distinct pathogenic mechanisms [PMID:32375064, PMID:23620143]. GALC haploinsufficiency also impairs microglial phagocytic clearance of myelin debris and remyelination capacity [PMID:28575206].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of GALC as the gene encoding galactosylceramidase established the molecular identity of the lysosomal enzyme responsible for galactosylceramide and psychosine catabolism.\",\n      \"evidence\": \"Biochemical purification from human urine/brain, cDNA cloning, and gene structure determination\",\n      \"pmids\": [\"7601472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Three-dimensional structure unknown\",\n        \"Mechanism of substrate presentation to the soluble enzyme not addressed\",\n        \"Determinants of enzyme trafficking to lysosomes not characterized\"\n      ]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that GALC is secreted and recaptured via mannose-6-phosphate receptors for lysosomal delivery established the cell biology of GALC trafficking and the basis for cross-correction therapy.\",\n      \"evidence\": \"Retroviral transduction of fibroblasts with secretion/uptake assays and mannose-6-phosphate receptor inhibition\",\n      \"pmids\": [\"8812733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Efficiency of cross-correction in vivo not tested\",\n        \"Post-translational processing steps for lysosomal maturation not defined\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Characterization of the GALC promoter as a GC-rich, TATA-less region with Sp1 sites and flanking inhibitory elements explained the constitutively low expression of GALC across cell types; splicing mutations (IVS6+5G>A) causing exon skipping and NMD were established as a disease mechanism.\",\n      \"evidence\": \"CAT reporter deletion constructs for promoter; mini-gene transfection for splice mutation\",\n      \"pmids\": [\"9441867\", \"10464649\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"In vivo promoter regulation and tissue-specific modulators not addressed\",\n        \"No systematic survey of splicing mutations\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that the twitcher nonsense mutation triggers NMD of GALC mRNA, and that lentiviral GALC localizes to lysosomes in neural cells with functional cross-correction, defined both a mRNA-level disease mechanism and a gene therapy rationale.\",\n      \"evidence\": \"NMD inhibitor rescue in twitcher Schwann cells; lentiviral transduction with lysosomal immunostaining and conditioned medium correction\",\n      \"pmids\": [\"16759875\", \"16732552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo cross-correction efficiency in CNS not determined\",\n        \"Relative contributions of NMD vs. protein instability for other mutations unknown\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The GALCtwi-5J missense mouse model showed that loss of GALC catalytic activity with normal precursor levels leads to psychosine accumulation and PNS-predominant dysmyelination, distinguishing a primary dysmyelination mechanism from secondary inflammatory demyelination.\",\n      \"evidence\": \"E130K missense knock-in mouse with enzyme activity, psychosine quantification, and neuropathology\",\n      \"pmids\": [\"23620143\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Why CNS myelin is relatively spared in this model not explained\",\n        \"Whether psychosine toxicity is direct or involves intermediate effectors unresolved\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolving the genotype-phenotype puzzle, subcellular fractionation demonstrated that lysosomal (not total cellular) GALC activity determines disease severity, with infantile mutations showing defective lysosomal trafficking and cis-polymorphisms modulating enzyme processing.\",\n      \"evidence\": \"Lysosomal fractionation, enzyme activity in lysosomes vs. whole-cell lysates, trafficking analysis of multiple GALC mutants\",\n      \"pmids\": [\"26865610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for trafficking defects not defined\",\n        \"How cis-polymorphisms mechanistically alter processing not fully resolved\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating that GALC haploinsufficiency impairs microglial phagocytosis and remyelination after demyelination revealed a non-cell-autonomous role for GALC in myelin repair beyond its canonical catabolic function.\",\n      \"evidence\": \"Cuprizone demyelination in GALC+/- mice with histology, Trem2 analysis, and pharmacological rescue\",\n      \"pmids\": [\"28575206\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether Trem2 reduction is a direct consequence of lipid substrate accumulation or an indirect effect is unclear\",\n        \"Relevance to human heterozygous carriers not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The crystal structure of the GALC–SapA complex revealed a heterotetrameric architecture with a channel connecting the active site to SapA's hydrophobic cavity, providing the structural basis for how a soluble hydrolase accesses lipid substrates embedded in membranes.\",\n      \"evidence\": \"X-ray crystallography with functional validation\",\n      \"pmids\": [\"29323104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How the complex assembles on lysosomal membranes in situ not resolved\",\n        \"Structural consequences of disease-causing mutations on the GALC–SapA interface not systematically mapped\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Cell-type-specific GALC ablation in mice dissected two independent disease mechanisms: autonomous psychosine-driven demyelination in Schwann cells and galactosylceramide-driven globoid cell transformation in macrophages causing secondary neuroinflammation.\",\n      \"evidence\": \"Cell-type-specific GALC-deficient mouse model with hematopoietic stem cell transplantation\",\n      \"pmids\": [\"32375064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contribution of each mechanism to human disease progression not quantified\",\n        \"Why cross-correction is inefficient in vivo not mechanistically explained\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A zebrafish GALC model revealed lactosylceramide as a neuroinflammatory metabolite accumulating upon GALC loss, broadening the pathogenic lipid repertoire beyond psychosine and galactosylceramide.\",\n      \"evidence\": \"CRISPR/Cas9 galcb knockout zebrafish with targeted lipidomics and intraventricular LacCer injection\",\n      \"pmids\": [\"40305757\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether LacCer accumulation occurs in mammalian Krabbe models not established\",\n        \"Enzymatic basis for LacCer as a GALC substrate vs. secondary metabolic effect unclear\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for how disease-causing mutations differentially affect lysosomal trafficking vs. catalytic activity, whether lactosylceramide accumulation contributes to human Krabbe pathogenesis, and the mechanism underlying inefficient in vivo cross-correction of GALC.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No systematic structure-function mapping of mutations onto GALC-SapA complex\",\n        \"Lactosylceramide role in mammalian models not tested\",\n        \"Determinants of in vivo cross-correction efficiency unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 3, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [1, 2, 3, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 4, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 4, 11]}\n    ],\n    \"complexes\": [\n      \"GALC-SapA heterotetramer\"\n    ],\n    \"partners\": [\n      \"PSAP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}